Related Experiment Videos
Using model complexes to augment and advance metalloproteinase inhibitor design
Faith E Jacobsen1, Seth M Cohen
1Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0358, USA.
Inorganic Chemistry
|May 11, 2004
Summary
Researchers explored how zinc complexes bind to various ligands, revealing that hydrogen bonding and acidity significantly influence binding modes. This provides key insights for designing new metalloproteinase inhibitors and advancing drug discovery for metalloproteins.
Area of Science:
- Coordination Chemistry
- Medicinal Chemistry
- Structural Biology
Background:
- Tetrahedral zinc complexes are relevant in biological systems and drug design.
- Understanding ligand binding modes is crucial for developing effective metalloproteinase inhibitors.
- Previous studies utilized structure-activity relationship by nuclear magnetic resonance (SAR by NMR) to assess potential ligands.
Purpose of the Study:
- To synthesize and characterize new tetrahedral zinc complexes with various zinc-binding groups (ZBGs).
- To determine the binding modes of these ZBGs within the zinc complex using X-ray crystallography.
- To investigate the influence of hydrogen bonding and ligand acidity on coordination behavior.
Main Methods:
- Synthesis of [(Tp(Ph,Me))ZnOH] complex.
- Reaction with diverse zinc-binding groups (e.g., salicylic acid, thiosalicylic acid derivatives).
- X-ray crystal structure determination of the resulting [(Tp(Ph,Me))Zn(ZBG)] complexes.
Main Results:
- Obtained X-ray crystal structures for multiple [(Tp(Ph,Me))Zn(ZBG)] complexes.
- Demonstrated that hydrogen bonding and donor atom acidity significantly affect ZBG binding modes.
- Identified specific coordination patterns influenced by ligand protonation and intramolecular hydrogen bonds.
Conclusions:
- Ligand protonation state and intramolecular hydrogen bonds critically influence coordination modes in metal-binding proteinase inhibitors.
- Model-based approaches can enhance drug discovery for metalloproteins.
- Findings support the development of second-generation metalloproteinase inhibitors.